Goldman Sachs analyst Matthew Sykes downgraded Nautilus Biotechnology (NAUT) to Sell from Neutral with a $1.75 price target which represents 21% downside to the current stock price. The firm believes the market for discovery proteomics has become more competitive with innovation from mass spec players, as Nautilus’ instrument launch timeline has been pushed out over time.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NAUT:
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue